• Investment set to Spur Oral Medicines Growth
    Andreas Ulrich
  • Company site at Wolfratshaus
  • Wolfsberg premises

News & Views

Investment set to Spur Oral Medicines Growth

Oct 06 2023

CDMO and full service provider Hermes Pharma is investing a further €25 million in its manufacturing capabilities, arming the company with new equipment, increased production and storage capacity, as well as greater operational efficiency to meet the rapidly growing market demand for user-friendly oral dosage forms. The investment forms part of the company’s strategy to drive future growth, while helping new and existing customers to realise theirs.

The pharmaceutical industry has long seen traditional tablets and capsules as the ‘gold standard’ of oral dosage forms. However, studies suggest that around 50% of people struggle to take them. Consequently, demand for easy-to-swallow oral dosage forms, such as orally disintegrating granules (ODGs), chewable tablets, lozenges, instant drinks and effervescents, is soaring, with healthcare companies seeking to add them to their portfolios.

Having specialised in user-friendly dosage forms for more than twenty years, the new investment in its specialist manufacturing plants, is focused on powering the company’s growth while unlocking greater scale, flexibility and cost-efficiency for customers. This will include new large-volume coating equipment to support growing need for advanced taste-masking; new filling and packaging lines for ODGs and instant drinks; expanded Good Manufacturing Practice (GMP) manufacturing and storage space; and optimised flow of inventory/goods on the shop floor.

“As pharmaceutical companies race to find ways to better serve patients and differentiate themselves in a competitive market, we’re seeing unprecedented demand for more patient-centric products,” said Dr Andreas Ulrich, COO of HERMES PHARMA . “Our latest investment will help us meet that demand, delivering ever greater service for our customers, while also helping us serve new customers across different market segments. We look forward to getting new and improved user-friendly dosage forms to patients quickly and more efficiently than ever before.”

More information online


Digital Edition

ILM 49.5 July

July 2024

Chromatography Articles - Understanding PFAS: Analysis and Implications Mass Spectrometry & Spectroscopy Articles - MS detection of Alzheimer’s blood-based biomarkers LIMS - Essent...

View all digital editions

Events

ADLM 2024

Jul 28 2024 San Diego, CA USA

InaLab 2024

Jul 30 2024 Jakarta, Indonesia

Miconex

Jul 31 2024 Chengdu, China

ACS National Meeting - Fall 2024

Aug 18 2024 Denver, CO, USA

EMC2024

Aug 25 2024 Copenhagen, Denmark

View all events